Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients

Abstract

Level of mutated cfDNA tends to correlate with MTB in advanced-stage NSCLC patients. Patients with detectable mutant DNA in plasma had an inferior survival, indicating that this could be an important predictor of survival.